透過您的圖書館登入
IP:3.149.254.110
  • 期刊
  • OpenAccess

Modulation of non-coding RNAs by resveratrol in ovarian cancer cells: In silico analysis and literature review of the anti-cancer pathways involved

摘要


Background and aim: Non-coding RNAs control cell functioning through affecting gene expression and translation and their dysregulation is associated with altered cell homeostasis and diseases, including cancer. Nutraceuticals with anti-cancer therapeutic potential have been shown to modulate non-coding RNAs expression that could impact on the expression of genes involved in the malignant phenotype. Experimental procedure: Here, we report on the microarray profiling of microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) and on the associated biochemical pathways and functional processes potentially modulated in OVCAR-3 ovarian cancer cells exposed for 24 h to Resveratrol (RV), a nutraceutical that has been shown to inhibit carcinogenesis and cancer progression in a variety of human and animal models, both in vitro and in vivo. Diana tools and Gene Ontology (GO) pathway analyses along with Pubmed literature search were employed to identify the cellular processes possibly affected by the dysregulated miRNAs and lncRNAs. Results and conclusion: The present data consistently support the contention that RV could exert antineoplastic activity via non-coding RNAs epigenetic modulation of the pathways governing cell homeostasis, cell proliferation, cell death and cell motility.

參考文獻


Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019 Jan Ca - Cancer J Clin. 2019;69(1):7-34. https://doi.org/10.3322/caac.21551. Epub 2019 Jan 8. PubMed PMID: 30620402.
Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013 Apr;10(4): 211-224. https://doi.org/10.1038/nrclinonc.2013.5. Epub 2013 Feb 5. Review.
Vaughan S, Coward JI, Bast Jr RC, Berchuck A, Berek JS, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Canc. 2011 Sep 23;11(10):719-725. https://doi.org/10.1038/nrc3144. PubMed PMID: 21941283; PubMed Central PMCID: PMC3380637.
Gupta KK, Gupta VK, Naumann RW. Ovarian cancer: screening and future directions. Int J Gynecol Canc. 2019 Jan;29(1):195-200. https://doi.org/10.1136/ijgc-2018-000016. Review. PubMed PMID: 30640704
Valente G, Nicotra G, Arrondini M, Castino R, Capparuccia L, et al. Co-expression of plexin-B1 and Met in human breast and ovary tumours enhances the risk of progression. Cell Oncol. 2009;31(6):423-436. https://doi.org/10.3233/CLO-2009-0504. PubMed PMID: 19940359; PubMed Central PMCID: PMC4619042

延伸閱讀